MENU
+Compare
ALLO
Stock ticker: NASDAQ
AS OF
Aug 15 closing price
Price
$1.10
Change
+$0.03 (+2.80%)
Capitalization
244.07M

ALLO Allogene Therapeutics Forecast, Technical & Fundamental Analysis

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases... Show more

Industry: #Biotechnology
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ALLO with price predictions
Aug 15, 2025

ALLO sees its Stochastic Oscillator recovers from oversold territory

On August 15, 2025, the Stochastic Oscillator for ALLO moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 63 instances where the indicator left the oversold zone. In of the 63 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 15, 2025. You may want to consider a long position or call options on ALLO as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ALLO advanced for three days, in of 243 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 137 cases where ALLO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for ALLO moved out of overbought territory on July 24, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for ALLO turned negative on July 31, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .

ALLO moved below its 50-day moving average on July 31, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ALLO crossed bearishly below the 50-day moving average on August 07, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALLO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ALLO broke above its upper Bollinger Band on July 21, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ALLO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.708) is normal, around the industry mean (19.528). P/E Ratio (0.000) is within average values for comparable stocks, (52.377). ALLO's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.945). Dividend Yield (0.000) settles around the average of (0.042) among similar stocks. ALLO's P/S Ratio (10000.000) is very high in comparison to the industry average of (294.394).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALLO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

ALLO is expected to report earnings to rise 2.22% to -23 cents per share on October 30

Allogene Therapeutics ALLO Stock Earnings Reports
Q3'25
Est.
$-0.24
Q2'25
Beat
by $0.04
Q1'25
Beat
by $0.01
Q4'24
Beat
by $0.04
Q3'24
Beat
by $0.01
The last earnings report on August 13 showed earnings per share of -23 cents, beating the estimate of -27 cents. With 5.89M shares outstanding, the current market capitalization sits at 244.07M.
A.I. Advisor
published General Information

General Information

a developer of allogeneic chimeric antigen receptor therapy

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
210 East Grand Avenue
Phone
+1 650 457-2700
Employees
233
Web
https://www.allogene.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NFLDF0.04N/A
+2.05%
Exploits Discovery Corp.
STBK11.190.13
+1.18%
Studio Financial Holdings, Inc.
SSAAY2.910.03
+1.04%
SSab Swedish Steel AB
DASTF31.450.30
+0.98%
Dassault Systemes SA
DMPZF2.79N/A
N/A
Domino's Pizza Australia New Zealand

ALLO and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ALLO has been loosely correlated with CRSP. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ALLO jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALLO
1D Price
Change %
ALLO100%
+2.80%
CRSP - ALLO
56%
Loosely correlated
+1.55%
FATE - ALLO
53%
Loosely correlated
+1.87%
NTLA - ALLO
52%
Loosely correlated
+0.83%
BEAM - ALLO
52%
Loosely correlated
+1.08%
RXRX - ALLO
48%
Loosely correlated
+2.30%
More